1. Introduction {#s0005}
===============

Intracranial germ cell tumors (IGCT) represent a histologically heterogeneous pediatric group of primary predominantly midline tumors of the CNS, most commonly seen in the pineal and the suprasellar region [@b0005], [@b0010], classically divided into two main groups: germinomas -- the most common --, and non-germinomatous GCT, which carry a less favorable prognosis [@b0015], [@b0020]. Germinomas are highly sensitive to both chemotherapy and radiotherapy (RT), and curable by RT alone [@b0005], [@b0010], [@b0020], either photons or protons [@b0025]. They present an excellent prognosis with overall survival of 93.7% five years after RT alone, 100% and 80.6% at 10- and 20-years, respectively [@b0005], [@b0030], [@b0035]. Macdonald showed early clinical outcomes of IGCT patients treated with protons where local control, progression-free survival, and overall survival rates were, respectively, 100%, 95%, and 100%, at a median follow-up of 28 months [@b0040]. Whole ventricular system irradiation followed by a boost to the tumor bed (WV-RT/TB) is considered a well-established treatment for localized germinomas{MacDonald, 2003 \#259} [@b0040].

There has been an effort for treatment de-escalation, due to: first, good response rates to neoadjuvant chemotherapy in non-disseminated disease [@b0045], with low leptomeningeal recurrence [@b0005]; second, noteworthy toxicity in long-term survivors [@b0035]. However, evaluating cerebral toxicity is extremely difficult as we only begin to understand the intricate interplay between the different substructures in physiological conditions, let alone in pathological conditions [@b0050]. Nonetheless, studies of Merchant et al. [@b0055] demonstrated that radiation dose-volume parameters remain the most clinically significant determinants of intelligence quotient (IQ) outcomes and that further reduction in radiation dose to specific volumes of the brain should be pursued [@b0060]. Relative to photons, hadron therapy could achieve even better protection of healthy tissues by improved beam trajectory [@b0040], having the potential to prevent the genesis of radiogenic impairment [@b0065], thus being expected to reduce late effects without decreasing local control and survival [@b0025].

However, taking into account that most of the neurofunctional organs at risk (NOAR) are partly enclosed or in the direct vicinity of the target, we hypothesized that there would not be a dosimetric advantage of pencil beam scanning proton therapy (PBS-PT) over a state of the art photon treatment technique. To the best of our knowledge, no dosimetric comparison based on WV-RT/TB has yet been made between PBS-PT and photon RT for non-metastatic IGCT with focus on NOAR sparing. Therefore, we performed a planning study with the aim of determining the dosimetric difference between intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT) on a cohort of IGCT patients treated with PBS-PT WV-RT/TB, using dose-volume indices of target volume coverage (TVC) and (N)OAR. Hereby, we compared the sparing potential of NOAR, currently used as a surrogate for neurocognition, cerebrovascular and neuroendocrine function, as well as other important structures, such as optic apparatus and cochleae, delineated on a routine basis for the planning of brain tumors RT.

2. Materials and methods {#s0010}
========================

2.1. Patient selection {#s0015}
----------------------

Between 2005 and 2017, 11 patients (8 males; 6--16 years, median 11) with a histologically proven diagnosis of localized IGCT were treated, after multi-agent chemotherapy, with PBS-PT at the Centre for Proton Therapy at the Paul-Scherrer Institute (PSI). They consisted of 2 bifocal germinomas, 4 pineal, 2 suprasellar, while 3 IGCT presented an atypical location with infiltrative spread within the ventricular system. Written, informed consent to the PBS-PT was obtained from the children legal guardians. Institutional review board approval was obtained before record and plan review. Complete anonymity of names and medical record numbers was maintained.

2.2. Target volume and organ at risk delineation {#s0020}
------------------------------------------------

First, all the 11 treatment planning-CTs and pre-irradiation MRI studies were anonymized and imported into a research database of Velocity (version 3.2.1, Varian Medical Systems, Inc., Palo Alto, USA). The MRIs were anatomically registered to the CT to facilitate volume definition. Then, for each patient, all volumes of interest (VOI) were delineated or adapted by a single radiation oncologist and reviewed by a neuro-radiation oncologist, as well as one neuroradiologist. For the purpose of this study, a 3 mm isometric margin, created on the same treatment planning software (TPS), was used for both planning treatment volumes (PTV). Delineation guidelines of the target volumes [@b0070] and (N)OAR [@b0075], as well as their dose constraints are detailed in the [supplementary file A](#s0140){ref-type="sec"}.

2.3. Treatment planning {#s0025}
-----------------------

The planning-CT data was sent in DICOM format, and all data transfers were made using file transfer protocol over Internet connections. The same VOI, dose prescription, and constraints were used to ensure comparability among the plans. The WV/TB were prescribed 24 Gy (PTV_Low), followed by a boost of 16 Gy to the TB (PTV_High), achieving a total dose of 40 Gy in 1.6 Gy per fraction. The plans were normalized to get 100% of the prescribed dose (D~p~) as the mean dose to each PTV. All treatment plans were optimized to maximize TVC whilst sparing OAR. Besides the hippocampi and temporal lobes, no further fixed constraint was set for the NOAR than the as low as reasonably achievable (ALARA) concept [@b0050], due to its location towards the target and lack of consensual constraints.

After trying and comparing different beam arrangements, all patients were treated with PBS-PT with three non-coplanar proton fields for both treatment series, with different gantry angulations and table rotation. Similar field arrangements have been used for the first phase and an adapted one for the boost (example in [Fig. 1](#f0005){ref-type="fig"}): one posterior field (G180deg, couch 0), two superior oblique fields (G90deg, couch 315--325 and G270deg, couch 35--45), in IEC61217 coordinate convention. All PBS-PT cases were planned with single field uniform dose, using the PSIPlan TPS (version 2.9.1-exp). The generic relative biologic effectiveness (RBE) factor for protons of 1.1 (relative to ^60^Co) was utilized, and proton dose was expressed in terms of Gy(RBE) (i.e., Gy(RBE) = proton physical Gy × 1.1) [@b0080]. The ion source was a dedicated 250 MeV cyclotron. Protons were actively delivered using a PBS paradigm, as previously described [@b0085]. Individual weights of the Bragg peak were computed using a dose based optimization scheme [@b0090] to obtain an optimal TVC. Proton dose calculation was performed using a 3D dose-calculation algorithm developed at PSI [@b0095].Fig. 1Comparison of dose distribution in three different modalities for a patient with intracranial germ cell tumor: (A) Pencil beam scanning proton beam therapy (PBS-PT) plan. (B) Intensity-modulated radiotherapy (IMRT) plan. (C) Volumetric modulated arc therapy (VMAT) plan. PTV_Low is delineated in orange, PTV_High in red. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

Comparison planning with IMRT and VMAT was performed on the original anonymized planning CT datasets and its respective study VOI. For the IMRT planning, after comparing with other beam arrangements, seven fields were used for the primary and five for the boost phase. The dose distribution of the photon plans was calculated with the Anisotropic Analytical Algorithm version 13.6.23, and optimized with the Dose Volume Optimizer version 11.0.31, on the Eclipse External Beam Planning (same version as described in [2.2](#s0020){ref-type="sec"}).

2.4. Comparative evaluation of treatment plans {#s0030}
----------------------------------------------

The proton plans were imported to Eclipse for comparison with the photon plans, where they were quantitatively assessed using dose-volume histograms (DVH) for all VOI. Dose parameters were extracted to evaluate proper TVC, assure compliance with the OAR dose constraints and determine differences between all RT modalities. TVC was assessed by the evaluation of the volume receiving a minimum of 90%, 95%, and 100% of the prescribed doses (V~90%~, V~95%~, V~100%~, respectively) [@b0065], [@b0100]. Dose distribution in the PTV was evaluated with the homogeneity index (HI) and inhomogeneity coefficient (IC). The integral dose (ID) ([Supplementary file](#s0140){ref-type="sec"}) allows the evaluation of the lower dose spread compared to conventional measurements [@b0105].

2.5. Statistics {#s0035}
---------------

Statistical analysis was performed on IBM® SPSS® Statistics software, version 24 (Armonk, NY). Descriptive statistics were used to calculate the differences in treatment parameters of proton and photon therapy. The Friedman test with the Bonferroni posttest was applied for analysis of statistically significant differences between several dosimetric parameters of the targets and (N)OAR of the proton and photon plans, with corresponding two-sided 95% confidence intervals to correct for multiple comparisons. A p-value inferior to 0.017 (Bonferroni correction) was considered statistically significant.

3. Results and discussion {#s0040}
=========================

3.1. Target volume coverage {#s0045}
---------------------------

Despite the normalization of each PTV (see [2.3](#s0025){ref-type="sec"}), after extracting the DVH values automatically with an Eclipse protocol template, a technical deviation ≤0.25% could be seen ([Table 1](#t0005){ref-type="table"}) if performed on another TPS than where it was planned. Therefore, the PBS-PT results should be critically appraised with the same amount of uncertainty. For this reason, only higher deviations (\>0.25%), statistically significant (p \< 0.017), will be mentioned.Table 1Comparison of target volume coverage and normal tissue sparing between PBS-PT, IMRT and VMAT.VOIParameterPBS-PTIMRTVMATPBS-PT vs. IMRT (%)PBS-PT vs. VMAT (%)IMRT vs. VMAT (%)PTV_LowD~max~ (%)106.8 ± 1.3107.0 ± 1.7107.2 ± 0.8−0.2−0.4−0.2D~mean~ (%)100.3 ± 0.6100.0 ± 0.0100.0 ± 0.00.20.20.0D~min~ (%)89.0 ± 2.070.4 ± 11.175.3 ± 10.226.4[\*](#tblfn1){ref-type="table-fn"}18.2[\*](#tblfn1){ref-type="table-fn"}−6.5Mean ID (Gy.ml)7620.8 ± 3572.97608.4 ± 3578.97608.4 ± 3578.90.20.20.0CoverageV~90%~ (%)99.9 ± 0.099.7 ± 0.099.9 ± 0.00.2[\*](#tblfn1){ref-type="table-fn"}0.0−0.2V~95%~ (%)99.1 ± 0.098.7 ± 0.099.3 ± 0.00.4−0.2−0.6V~100%~ (%)63.9 ± 0.159.7 ± 0.255.2 ± 0.07.015.88.2Dose distributionHI4.9 ± 0.55.5 ± 1.53.5 ± 0.6−10.940.0[\*](#tblfn1){ref-type="table-fn"}57.1[\*](#tblfn1){ref-type="table-fn"}IC0.2 ± 0.00.4 ± 0.10.3 ± 0.1−50.0[\*](#tblfn1){ref-type="table-fn"}−33.3[\*](#tblfn1){ref-type="table-fn"}33.3PTV_HighD~max~ (%)104.7 ± 1.6105.8 ± 2.1106.1 ± 1.5−1.0−1.3−0.3D~mean~ (%)100.1 ± 0.1100.0 ± 0.0100.0 ± 0.00.1[\*](#tblfn1){ref-type="table-fn"}0.1[\*](#tblfn1){ref-type="table-fn"}0.0D~min~ (%)89.4 ± 2.877.1 ± 7.482.9 ± 3.915.9[\*](#tblfn1){ref-type="table-fn"}7.8[\*](#tblfn1){ref-type="table-fn"}−7.0[\*](#tblfn1){ref-type="table-fn"}Mean ID (Gy.ml)1909.1 ± 2346.41907.4 ± 2345.11907.4 ± 2345.10.1[\*](#tblfn1){ref-type="table-fn"}0.1[\*](#tblfn1){ref-type="table-fn"}0.0CoverageV~90%~ (%)99.7 ± 0.099.3 ± 0.099.9 ± 0.00.40.2−0.6V~95%~ (%)98.4 ± 0.093.5 ± 0.298.2 ± 0.05.20.2−4.8V~100%~ (%)70.8 ± 0.155.9 ± 0.257.8 ± 0.026.722.5[\*](#tblfn1){ref-type="table-fn"}−3.3Dose distributionHI4.7 ± 1.06.4 ± 1.25.0 ± 1.4−26.6[\*](#tblfn1){ref-type="table-fn"}−6.028.0IC0.2 ± 0.00.3 ± 0.10.2 ± 0.0−44.8[\*](#tblfn1){ref-type="table-fn"}−30.4[\*](#tblfn1){ref-type="table-fn"}26.1CTV_LowD~max~ (%)106.5 ± 1.1105.9 ± 1.2106.4 ± 1.40.60.1−0.5D~mean~ (%)100.6 ± 0.2100.2 ± 0.1100.2 ± 0.10.4[\*](#tblfn1){ref-type="table-fn"}0.4[\*](#tblfn1){ref-type="table-fn"}0.0Mean ID (Gy.ml)5111.7 ± 2913.95103.5 ± 2905.05092.6 ± 2905.90.3[\*](#tblfn1){ref-type="table-fn"}0.4[\*](#tblfn1){ref-type="table-fn"}0.0CTV_HighD~max~ (%)104.2 ± 1.2104.5 ± 3.1105.5 ± 1.4−0.3−1.2−0.9D~mean~ (%)100.7 ± 0.2100.3 ± 0.2100.3 ± 0.10.4[\*](#tblfn1){ref-type="table-fn"}0.4[\*](#tblfn1){ref-type="table-fn"}0.0Mean ID (Gy.ml)1300.6 ± 1747.21297.0 ± 1742.01298.0 ± 1745.20.3[\*](#tblfn1){ref-type="table-fn"}0.4[\*](#tblfn1){ref-type="table-fn"}0.1GTV_LowD~max~ (%)104.0 ± 1.5105.4 ± 1.3103.3 ± 1.2−1.30.72.0[\*](#tblfn1){ref-type="table-fn"}D~mean~ (%)100.3 ± 0.2100.4 ± 0.3100.0 ± 0.1−0.10.3[\*](#tblfn1){ref-type="table-fn"}0.4[\*](#tblfn1){ref-type="table-fn"}Mean ID (Gy.ml)1975.9 ± 1717.11978.1 ± 1719.71972.0 ± 1716.6−0.10.2[\*](#tblfn1){ref-type="table-fn"}0.3[\*](#tblfn1){ref-type="table-fn"}GTV_HighD~max~ (%)102.6 ± 1.1103.9 ± 2.5102.6 ± 1.1−1.30.01.3D~mean~ (%)100.6 ± 0.3100.4 ± 0.5100.0 ± 0.10.20.6[\*](#tblfn1){ref-type="table-fn"}0.4Mean ID (Gy.ml)588.6 ± 926.9589.6 ± 929.0588.4 ± 921.9−0.20.2[\*](#tblfn1){ref-type="table-fn"}0.0Amygdala leftD~max~ (%)91.4 ± 16.489.7 ± 15.993.5 ± 11.71.9−2.2−4.1D~mean~ (%)79.7 ± 18.277.0 ± 17.585.0 ± 14.33.5−6.2−9.4[\*](#tblfn1){ref-type="table-fn"}Mean ID (Gy.ml)52.5 ± 26.650.8 ± 23.655.7 ± 22.73.3−5.7−8.8[\*](#tblfn1){ref-type="table-fn"}Amygdala rightD~max~ (%)89.1 ± 16.187.6 ± 15.592.3 ± 11.51.73.5−5.1D~mean~ (%)79.1 ± 17.777.3 ± 16.884.4 ± 13.12.3−6.3−8.4[\*](#tblfn1){ref-type="table-fn"}Mean ID (Gy.ml)60.7 ± 26.459.3 ± 26.164.4 ± 24.62.4−5.7−7.9[\*](#tblfn1){ref-type="table-fn"}BrainstemD~max~ (%)102.1 ± 0.6102.6 ± 1.0102.9 ± 0.9−0.5−0.8−0.3D~mean~ (%)74.8 ± 7.282.4 ± 6.077.3 ± 8.0−9.2[\*](#tblfn1){ref-type="table-fn"}−3.26.6Mean ID (Gy.ml)706.1 ± 130.2777.4 ± 136.0730.4 ± 144.7−9.2[\*](#tblfn1){ref-type="table-fn"}−3.36.4CerebellumD~max~ (%)99.1 ± 4.7101.1 ± 2.7100.1 ± 4.3−2.0−1.01.0D~mean~ (%)25.7 ± 3.455.5 ± 7.638.4 ± 4.3−53.7[\*](#tblfn1){ref-type="table-fn"}−33.1[\*](#tblfn1){ref-type="table-fn"}44.5[\*](#tblfn1){ref-type="table-fn"}Mean ID (Gy.ml)1423.0 ± 309.03069.0 ± 692.02115.3 ± 376.9−53.6[\*](#tblfn1){ref-type="table-fn"}−32.7[\*](#tblfn1){ref-type="table-fn"}45.1[\*](#tblfn1){ref-type="table-fn"}ChiasmD~max~ (%)91.2 ± 16.190.3 ± 15.491.8 ± 13.70.1−0.7−1.6\
−5.1\
−4.9D~mean~ (%)73.0 ± 27.374.4 ± 24.778.4 ± 21.9−1.9−6.9Mean ID (Gy.ml)11.5 ± 6.011.6 ± 5.212.2 ± 5.1−0.9−5.7Circle of WillisD~max~ (%)102.6 ± 2.2101.2 ± 2.796.8 ± 20.11.46.04.5D~mean~ (%)63.8 ± 24.368.7 ± 22.067.5 ± 26.2−7.1[\*](#tblfn1){ref-type="table-fn"}−5.51.8Mean ID (Gy.ml)85.6 ± 31.592.8 ± 29.690.5 ± 37.8−7.8[\*](#tblfn1){ref-type="table-fn"}−5.42.5Cochlea leftD~max~ (%)21.0 ± 11.625.9 ± 6.617.0 ± 6.5−18.923.552.5[\*](#tblfn1){ref-type="table-fn"}D~mean~ (%)12.0 ± 7.918.9 ± 4.213.2 ± 4.0−36.5−9.143.2[\*](#tblfn1){ref-type="table-fn"}\
33.3[\*](#tblfn1){ref-type="table-fn"}Mean ID (Gy.ml)0.5 ± 0.30.8 ± 0.30.6 ± 0.2−40.5−20.7Cochlea rightD~max~ (%)22.8 ± 17.924.5 ± 6.717.8 ± 6.9−6.928.137.6[\*](#tblfn1){ref-type="table-fn"}D~mean~ (%)13.3 ± 10.918.6 ± 4.213.5 ± 4.5−28.5−1.537.8[\*](#tblfn1){ref-type="table-fn"}Mean ID (Gy.ml)0.5 ± 0.40.7 ± 0.20.5 ± 0.2−28.60.040.0[\*](#tblfn1){ref-type="table-fn"}Hippocampus leftD~max~ (%)101.1 ± 0.5101.1 ± 0.7101.4 ± 0.50.0−0.3−0.3D~mean~ (%)84.5 ± 10.579.6 ± 11.789.2 ± 7.96.2[\*](#tblfn1){ref-type="table-fn"}−5.3−10.8[\*](#tblfn1){ref-type="table-fn"}Mean ID (Gy.ml)109.9 ± 37.9103.6 ± 37.5116.1 ± 37.86.1[\*](#tblfn1){ref-type="table-fn"}−5.3−10.8[\*](#tblfn1){ref-type="table-fn"}D~40%~ (%)87.8 ± 13.284.9 ± 11.891.1 ± 8.03.4−4.4−7.5Hippocampus rightDmax97.5 ± 12.098.3 ± 8.099.5 ± 6.1−0.8−2.0−1.2Dmean79.6 ± 12.476.3 ± 11.786.4 ± 8.94.3−7.9−11.7[\*](#tblfn1){ref-type="table-fn"}Mean ID (Gy.ml)110.1 ± 35.3102.5 ± 33.6119.6 ± 37.47.4−7.9−14.3[\*](#tblfn1){ref-type="table-fn"}D~40%~ (%)79.4 ± 14.078.3 ± 13.487.5 ± 8.91.4−9.3−10.5Hypothalamus leftD~max~ (%)100.9 ± 0.3102.0 ± 1.0101.1 ± 0.5−1.1−0.20.9D~mean~ (%)97.8 ± 7.897.8 ± 6.197.2 ± 6.40.00.6[\*](#tblfn1){ref-type="table-fn"}0.6Mean ID (Gy.ml)11.3 ± 5.611.3 ± 5.511.2 ± 5.60.00.9[\*](#tblfn1){ref-type="table-fn"}0.9Hypothalamus rightD~max~ (%)100.7 ± 1.1101.7 ± 2.1100.5 ± 2.9−1.00.21.2[\*](#tblfn1){ref-type="table-fn"}D~mean~ (%)97.8 ± 8.197.9 ± 6.397.1 ± 7.0−0.10.70.8Mean ID (Gy.ml)11.6 ± 5.511.6 ± 5.411.6 ± 5.50.00.00.0Lacrimal gland leftD~max~ (%)6.6 ± 17.18.6 ± 7.218.5 ± 6.9−23.3[\*](#tblfn1){ref-type="table-fn"}−64.3[\*](#tblfn1){ref-type="table-fn"}−53.5[\*](#tblfn1){ref-type="table-fn"}D~mean~ (%)2.6 ± 7.25.7 ± 4.522.2 ± 27.0−54.4[\*](#tblfn1){ref-type="table-fn"}−88.3[\*](#tblfn1){ref-type="table-fn"}−74.3[\*](#tblfn1){ref-type="table-fn"}Mean ID (Gy.ml)0.4 ± 1.20.9 ± 0.83.8 ± 5.6−57.6[\*](#tblfn1){ref-type="table-fn"}−89.5[\*](#tblfn1){ref-type="table-fn"}−75.2[\*](#tblfn1){ref-type="table-fn"}Lacrimal gland rightD~max~ (%)1.3 ± 3.27.6 ± 5.817.7 ± 6.4−82.9[\*](#tblfn1){ref-type="table-fn"}−92.7[\*](#tblfn1){ref-type="table-fn"}−57.1[\*](#tblfn1){ref-type="table-fn"}D~mean~ (%)0.3 ± 0.85.3 ± 4.313.5 ± 6.1−94.3[\*](#tblfn1){ref-type="table-fn"}−97.8[\*](#tblfn1){ref-type="table-fn"}−60.7[\*](#tblfn1){ref-type="table-fn"}Mean ID (Gy.ml)0.0 ± 0.10.8 ± 0.52.1 ± 0.8−95.8[\*](#tblfn1){ref-type="table-fn"}−98.4[\*](#tblfn1){ref-type="table-fn"}−61.9[\*](#tblfn1){ref-type="table-fn"}Lens leftD~max~ (%)0.4 ± 1.34.1 ± 2.510.9 ± 4.8−90.2[\*](#tblfn1){ref-type="table-fn"}−96.3[\*](#tblfn1){ref-type="table-fn"}−62.4[\*](#tblfn1){ref-type="table-fn"}D~mean~ (%)0.2 ± 0.63.7 ± 2.19.3 ± 4.0−94.6[\*](#tblfn1){ref-type="table-fn"}−97.8[\*](#tblfn1){ref-type="table-fn"}−60.2[\*](#tblfn1){ref-type="table-fn"}Mean ID (Gy.ml)0.0 ± 0.00.3 ± 0.20.8 ± 0.4−100.0[\*](#tblfn1){ref-type="table-fn"}−100.0[\*](#tblfn1){ref-type="table-fn"}−62.5[\*](#tblfn1){ref-type="table-fn"}Lens rightD~max~ (%)0.0 ± 0.03.9 ± 2.111.1 ± 5.0−100.0[\*](#tblfn1){ref-type="table-fn"}−100.0[\*](#tblfn1){ref-type="table-fn"}−64.9[\*](#tblfn1){ref-type="table-fn"}D~mean~ (%)0.0 ± 0.03.6 ± 1.99.4 ± 4.1−100.0[\*](#tblfn1){ref-type="table-fn"}−100.0[\*](#tblfn1){ref-type="table-fn"}−61.7[\*](#tblfn1){ref-type="table-fn"}Mean ID (Gy.ml)0.0 ± 0.00.3 ± 0.10.7 ± 0.2−100.0[\*](#tblfn1){ref-type="table-fn"}−100.0[\*](#tblfn1){ref-type="table-fn"}−58.2[\*](#tblfn1){ref-type="table-fn"}Normal brain (brain minus PTV)D~max~ (%)100.7 ± 0.5103.3 ± 1.6102.3 ± 1.5−2.5[\*](#tblfn1){ref-type="table-fn"}−1.6[\*](#tblfn1){ref-type="table-fn"}1.0D~mean~ (%)30.0 ± 8.646.3 ± 10.044.6 ± 9.1−35.2[\*](#tblfn1){ref-type="table-fn"}−32.7[\*](#tblfn1){ref-type="table-fn"}3.8Mean ID (Gy.ml)12211.7 ± 3402.818846.4± 3924.718226.7± 3887.2−35.2[\*](#tblfn1){ref-type="table-fn"}−33.0[\*](#tblfn1){ref-type="table-fn"}3.4Optic globe leftD~max~ (%)8.6 ± 23.612.0 ± 14.822.9 ± 12.4−28.3[\*](#tblfn1){ref-type="table-fn"}−62.4[\*](#tblfn1){ref-type="table-fn"}−47.6[\*](#tblfn1){ref-type="table-fn"}D~mean~ (%)1.0 ± 3.25.2 ± 4.413.9 ± 6.8−80.8[\*](#tblfn1){ref-type="table-fn"}−92.8[\*](#tblfn1){ref-type="table-fn"}−62.6[\*](#tblfn1){ref-type="table-fn"}Mean ID (Gy.ml)3.3 ± 10.416.1 ± 14.342.3 ± 21.4−79.5[\*](#tblfn1){ref-type="table-fn"}−92.2[\*](#tblfn1){ref-type="table-fn"}−61.9[\*](#tblfn1){ref-type="table-fn"}Optic globe rightD~max~ (%)2.0 ± 3.58.9 ± 6.820.5 ± 0.8−77.5[\*](#tblfn1){ref-type="table-fn"}−90.2[\*](#tblfn1){ref-type="table-fn"}−56.6[\*](#tblfn1){ref-type="table-fn"}D~mean~ (%)0.1 ± 0.24.7 ± 0.213.2 ± 6.7−97.9[\*](#tblfn1){ref-type="table-fn"}−99.2[\*](#tblfn1){ref-type="table-fn"}−64.4[\*](#tblfn1){ref-type="table-fn"}Mean ID (Gy.ml)0.3 ± 0.614.8 ± 11.640.3 ± 22.4−98.2[\*](#tblfn1){ref-type="table-fn"}−99.3[\*](#tblfn1){ref-type="table-fn"}−63.3[\*](#tblfn1){ref-type="table-fn"}Optic nerve leftD~max~ (%)65.4 ± 42.458.8 ± 38.261.3 ± 35.511.26.7−4.1D~mean~ (%)20.4 ± 22.624.1 ± 20.030.5 ± 19.2−15.4−33.1[\*](#tblfn1){ref-type="table-fn"}−21.0[\*](#tblfn1){ref-type="table-fn"}Mean ID (Gy.ml)2.5 ± 2.43.2 ± 1.94.2 ± 1.9−21.9−40.5−23.8[\*](#tblfn1){ref-type="table-fn"}Optic nerve rightD~max~ (%)62.9 ± 38.756.3 ± 38.859.0 ± 36.011.76.6−4.6D~mean~ (%)15.7 ± 22.322.1 ± 19.628.7 ± 19.4−29.0−45.3[\*](#tblfn1){ref-type="table-fn"}−23.0[\*](#tblfn1){ref-type="table-fn"}Mean ID (Gy.ml)1.9 ± 2.12.9 ± 1.83.9 ± 1.8−34.5−51.3[\*](#tblfn1){ref-type="table-fn"}−25.6[\*](#tblfn1){ref-type="table-fn"}Parotid leftD~max~ (%)0.6 ± 1.818.2 ± 6.79.7 ± 2.6−96.7[\*](#tblfn1){ref-type="table-fn"}−93.8[\*](#tblfn1){ref-type="table-fn"}87.6[\*](#tblfn1){ref-type="table-fn"}D~mean~ (%)0.0 ± 0.05.9 ± 1.95.5 ± 1.8−100.0[\*](#tblfn1){ref-type="table-fn"}−100.0[\*](#tblfn1){ref-type="table-fn"}7.3Mean ID (Gy.ml)0.0 ± 0.025.6 ± 11.925.5 ± 19.8−100.0[\*](#tblfn1){ref-type="table-fn"}−100.0[\*](#tblfn1){ref-type="table-fn"}0.4Parotid rightD~max~ (%)0.3 ± 0.716.7 ± 5.98.9 ± 2.0−98.2[\*](#tblfn1){ref-type="table-fn"}−96.6[\*](#tblfn1){ref-type="table-fn"}87.6[\*](#tblfn1){ref-type="table-fn"}D~mean~ (%)0.0 ± 0.05.7 ± 2.15.1 ± 1.4−100.0[\*](#tblfn1){ref-type="table-fn"}−100.0[\*](#tblfn1){ref-type="table-fn"}11.8Mean ID (Gy.ml)0.0 ± 0.024.6 ± 13.322.6 ± 13.2−100.0[\*](#tblfn1){ref-type="table-fn"}−100.0[\*](#tblfn1){ref-type="table-fn"}8.8PituitaryD~max~ (%)68.9 ± 32.563.2 ± 34.560.8 ± 37.49.013.33.9D~mean~ (%)54.5 ± 41.253.6 ± 39.653.9 ± 39.41.71.10.6Mean ID (Gy.ml)11.4 ± 15.211.3 ± 14.911.4 ± 14.90.90.0−0.9SkinD~max~ (%)38.7 ± 25.046.7 ± 6.047.5 ± 9.7−17.1−18.5−1.7D~mean~ (%)13.8 ± 19.29.0 ± 2.88.0 ± 2.253.372.512.5Mean ID (Gy.ml)701.5 ± 774.4612.2 ± 357.3553.6 ± 343.314.626.710.6Spinal cordD~max~ (%)54.8 ± 11.751.2 ± 19.446.1 ± 22.17.018.911.1D~mean~ (%)13.1 ± 8.312.4 ± 7.88.9 ± 6.55.647.2[\*](#tblfn1){ref-type="table-fn"}39.3[\*](#tblfn1){ref-type="table-fn"}Mean ID (Gy.ml)22.2 ± 13.821.9 ± 14.215.3 ± 11.11.445.1[\*](#tblfn1){ref-type="table-fn"}43.1[\*](#tblfn1){ref-type="table-fn"}SupratentorialD~max~ (%)103.2 ± 1.6103.9 ± 1.6103.4 ± 1.1−0.7−0.20.5D~mean~ (%)39.8 ± 11.952.2 ± 11.950.2 ± 11.3−23.8[\*](#tblfn1){ref-type="table-fn"}−20.7[\*](#tblfn1){ref-type="table-fn"}4.0Mean ID (Gy.ml)36821.3± 65329.347163.9± 81511.646058.0 ± 80876.5−21.9[\*](#tblfn1){ref-type="table-fn"}−20.1[\*](#tblfn1){ref-type="table-fn"}2.4SVZ leftD~max~ (%)99.0 ± 5.399.2 ± 5.898.6 ± 6.8−0.20.40.6D~mean~ (%)76.5 ± 11.375.5 ± 11.980.5 ± 10.71.3−5.0[\*](#tblfn1){ref-type="table-fn"}−6.2[\*](#tblfn1){ref-type="table-fn"}Mean ID (Gy.ml)192.7 ± 159.8193.6 ± 167.6202.0 ± 164.8−0.5−4.6[\*](#tblfn1){ref-type="table-fn"}−4.2[\*](#tblfn1){ref-type="table-fn"}SVZ rightD~max~ (%)93.6 ± 12.395.5 ± 11.196.1 ± 8.3−2.0[\*](#tblfn1){ref-type="table-fn"}−2.6[\*](#tblfn1){ref-type="table-fn"}−0.6D~mean~ (%)73.7 ± 11.973.3 ± 11.978.9 ± 10.50.5−6.6[\*](#tblfn1){ref-type="table-fn"}−7.1Mean ID (Gy.ml)177.3 ± 148.3179.5 ± 156.8188.4 ± 153.0−1.2−5.9[\*](#tblfn1){ref-type="table-fn"}−4.7Temporal lobe leftD~max~ (%)101.0 ± 3.7100.9 ± 5.0101.1 ± 4.10.1−0.1−0.2D~mean~ (%)49.0 ± 19.550.5 ± 13.458.8 ± 19.9−3.0[\*](#tblfn1){ref-type="table-fn"}−16.7−14.1[\*](#tblfn1){ref-type="table-fn"}Mean ID (Gy.ml)2444.9 ± 1406.62455.2 ± 899.22819.5 ± 1211.3−0.4[\*](#tblfn1){ref-type="table-fn"}−13.3−12.9[\*](#tblfn1){ref-type="table-fn"}V~20Gy~ (%)107.4 ± 37.7134.7 ± 55.6177.8 ± 42.4−20.3−39.6[\*](#tblfn1){ref-type="table-fn"}−24.2[\*](#tblfn1){ref-type="table-fn"}Temporal lobe rightD~max~ (%)97.0 ± 10.197.7 ± 8.399.7 ± 5.8−0.7−2.7−2.0[\*](#tblfn1){ref-type="table-fn"}D~mean~ (%)43.1 ± 14.050.4 ± 14.163.3 ± 12.5−14.5[\*](#tblfn1){ref-type="table-fn"}−31.9[\*](#tblfn1){ref-type="table-fn"}−20.4[\*](#tblfn1){ref-type="table-fn"}Mean ID (Gy.ml)4621.6 ± 8441.55420.9 ± 9931.56588.9 ± 51.5−14.7[\*](#tblfn1){ref-type="table-fn"}−29.9[\*](#tblfn1){ref-type="table-fn"}−17.7[\*](#tblfn1){ref-type="table-fn"}Thalamus leftV~20Gy~ (%)104.2 ± 36.5137.4 ± 51.5177.0 ± 42.0−24.2[\*](#tblfn1){ref-type="table-fn"}−41.1[\*](#tblfn1){ref-type="table-fn"}−22.4[\*](#tblfn1){ref-type="table-fn"}D~max~ (%)101.1 ± 0.4102.5 ± 1.2101.9 ± 0.6−1.4−0.8[\*](#tblfn1){ref-type="table-fn"}0.6D~mean~ (%)96.5 ± 3.696.2 ± 3.895.3 ± 5.60.31.30.9Mean ID (Gy.ml)214.8 ± 44.8214.6 ± 47.3211.6 ± 42.60.11.51.4Thalamus rightD~max~ (%)101.2 ± 0.4102.4 ± 1.1102.1 ± 0.8−1.2−0.90.3D~mean~ (%)93.4 ± 8.093.5 ± 6.494.8 ± 4.6−0.1−1.5−1.4Mean ID (Gy.ml)211.2 ± 44.9211.8 ± 46.0214.3 ± 44.4−0.3−1.4−1.2TMJ leftD~max~ (%)9.7 ± 8.716.5 ± 8.012.0 ± 4.4−44.6[\*](#tblfn1){ref-type="table-fn"}−19.245.8[\*](#tblfn1){ref-type="table-fn"}D~mean~ (%)1.0 ± 1.29.9 ± 3.68.5 ± 2.6−89.9[\*](#tblfn1){ref-type="table-fn"}−88.2[\*](#tblfn1){ref-type="table-fn"}16.5Mean ID (Gy.ml)0.9 ± 1.38.1 ± 3.97.0 ± 3.3−88.7[\*](#tblfn1){ref-type="table-fn"}−87.0[\*](#tblfn1){ref-type="table-fn"}15.7TMJ rightD~max~ (%)10.7 ± 11.818.0 ± 8.712.7 ± 4.6−40.6[\*](#tblfn1){ref-type="table-fn"}−15.741.7[\*](#tblfn1){ref-type="table-fn"}D~mean~ (%)1.3 ± 1.89.7 ± 4.28.6 ± 2.6−86.1[\*](#tblfn1){ref-type="table-fn"}−83.8[\*](#tblfn1){ref-type="table-fn"}16.2Mean ID (Gy.ml)1.1 ± 1.67.9 ± 4.56.8 ± 3.3−86.0[\*](#tblfn1){ref-type="table-fn"}−83.8[\*](#tblfn1){ref-type="table-fn"}16.2Values are given as mean relative dose with standard deviations in percentage (%):-- Primary phase(PTV_Low, CTV_Low, GTV_Low)24 Gy= 100%-- Boost phase(PTV_High, CTV_High, GTV_High)16 Gy-- Organs at riskAll other VOI40 Gy[^1][^2]

TVC was comparable for all three modalities ([Fig. 2](#f0010){ref-type="fig"}). However, PBS-PT achieved a better V~100%~ (22.5%) in PTV_High, compared to VMAT.Fig. 2Cumulative dose-volume histograms (DVH) (mean dose, n = 11) with range for PTV coverage with PBS-PT, IMRT and VMAT plans.

Comparing to IMRT and VMAT, both PTV showed with PBS-PT a higher minimum dose (D~min~) to the PTV (PTV_Low: 26.4%, 18.2%; PTV_High: 15.9%, 7.8%). Both IC were significantly lower for protons (PTV_Low: −50.0%, −33.3%; PTV_High: −44.8%, −30.4%), indicating a lower variability of the target dose distribution in PBS-PT than in the photon modalities.

The dose distribution homogeneity on the primary phase was optimized in the VMAT plans, as the PTV_Low HI was significantly lower than the other RT techniques, while PBS-PT was better than IMRT on the boost phase ([Table 1](#t0005){ref-type="table"}).

3.2. Neurofunctional organ at risk sparing {#s0050}
------------------------------------------

For the OARs, 100% was considered to be 40 Gy ([Table 1](#t0005){ref-type="table"}). All hard constraints were met, independently of the technique used.

### 3.2.1. NOAR of neurocognitive function {#s0055}

The hippocampal and amygdalae D~mean~ and ID seem better spared with IMRT than VMAT, while on the left hippocampus the IMRT dose sparing seems higher than with the remaining techniques (−6.2% D~mean~, −6.1% ID than PBS-PT; −10.8% D~mean~ and ID each, comparing with VMAT). However, taking into account the hippocampal proximity to the target, its soft constraint of D40% ≤7.3 Gy could never be reached -- its lowest absolute dose was 24.2 Gy on one PBS-PT plan.

There is growing evidence from structural and functional imaging studies that the cerebellum plays an evident role in neurocognition. Radiation to the posterior fossa has shown to have a negative effect on neurocognitive outcomes in long-term pediatric brain survivors [@b0060]. Gan et al. described that the patient with the lowest neuropsychological scores received 36 Gy D~max~ on the cerebellum and low radiation doses on the whole brain and hippocampi [@b0110]. In our cohort, only one case (PBS-PT) achieved a D~max~ \< 36 Gy, otherwise, the PBS-PT average was 39.6 Gy (range, 35.5--41.6 Gy). However, the statistically significant difference to IMRT and VMAT could be seen on D~mean~ (−53.7%, −33.1%) and ID (-53.6%, −32.7%), favoring the proton over the photon plans. Between IMRT and VMAT, the latter seems dosimetrically beneficial (−44.5% Dmean; −45.1% ID) regarding cerebellum dose exposure ([Fig. 3](#f0015){ref-type="fig"}).Fig. 3Cumulative DVH (mean dose, n = 11) with range for (N)OAR with a significant dose difference for PBS-PT compared to photons.

Compared to IMRT and VMAT, PBS-PT showed the following statistically significant reduction in:•temporal lobe -- D~mean~ (−14.5%, −31.9%), ID (−14.7%, −29.9%), V~20Gy~ (−24.2%, −41.1%) on the right side. Moreover, the left temporal lobe dose sparing was higher with protons (PBS-PT D~mean~, ID better than IMRT; PBS-PT V~20Gy~ better than VMAT). Compared to VMAT, IMRT seems advantageous in both lobes.•subventricular zone (SVZ) -- maximum dose (D~max~) (−2.0%, −2.6%) on the right side. Furthermore, VMAT had the least dose sparing in comparison to the other two modalities (PBS-PT D~mean~ and ID better spared on both sides, while IMRT D~mean~ and ID on the left side).

Neurons and glial cells are produced from neurogenic stem cells located in the SVZ of the lateral ventricles and the subgranular zone of the hippocampal gyrus. These areas form part of the limbic system, located in the temporal lobe. They have important roles in various aspects of memory and emotional learning [@b0115] and are very susceptible to radiation-induced damage, particularly in the developing tissues of young patients [@b0120]. A dose-dependent thinning of the cerebral cortex was described, with a pronounced effect in the temporal lobes and limbic cortex [@b0125]. The proposed dose constraint for the hippocampi is currently D~40%~ ≤ 7.3 Gy to avoid memory loss [@b0050]. Prospective data demonstrate not only a significant association between increasing dose to the hippocampus and temporal lobes and decline in neurocognitive skills following cranial irradiation [@b0130], but also with the dose and volume of the irradiated healthy brain and the IQ [@b0135]. Age was also an important determinant of impact on IQ, with younger children being more sensitive to neurocognitive effects of RT [@b0055], [@b0140]. Especially in this population, a decrease in IQ, processing speed, and fine motor skills have been reported after chemoradiation, with memory impairment associated with a D~max~ \> 30 Gy to the temporal lobe [@b0145]. When normal tissue volumes such as the supratentorial brain or temporal lobes receive less of the low and intermediate doses [@b0140], it resulted in clinically significant higher IQ scores for patients with intracranial tumors [@b0150].

### 3.2.2. NOAR of cerebrovascular function {#s0060}

PBS-PT allowed for a statistically significant difference of −7.1% D~mean~ and −7.8% ID of the Willis' circle, when compared to IMRT.

El-Fayech et al. reported that at 45 years of age, the cumulative stroke incidence was 11.3% in patients who had received D~mean~ ≥ 10 Gy to the Willis' circle as children, compared with 1% expected from general population data [@b0155]. In our cohort, the D~mean~ applied to the Willis' circle was 25.5 Gy (range, 10.3--39.7 Gy) for PBS-PT, 27.5 Gy (range, 14.1−39.7 Gy) for IMRT and 27.0 Gy (range, 2.5--39.4 Gy) for VMAT. Nevertheless, the ALARA concept seems to play an important role on the potential of decreasing the likelihood of vascular sequelae: an association of 5% stroke hazard increase per 1 Gy (D~mean~) mainly to the Willis' circle was estimated in a longitudinal data set of \>10,000 cancer survivors [@b0160], thus showing a dose-dependent effect (almost 30-fold higher risk of stroke after cranial RT than the general population) [@b0155].

### 3.2.3. NOAR of neuroendocrine function {#s0065}

Regarding the hypothalamic-pituitary axis, only the VMAT D~mean~ and ID of the left hypothalamus were significantly lower (−0.6% and −0.9%, respectively) comparing with PBS-PT and D~max~ (−1.2%) comparing with IMRT.

Even low dose on the hypothalamic-pituitary axis influences the occurrence of endocrinopathy [@b0095]. Pai et al. reported that D~mean~ \< 20 Gy(RBE) to the hypothalamus was associated with endocrinopathy, even though this association was only found for a D~min~ \> 50 Gy(RBE) for the pituitary gland [@b0165]. Chemaitilly et al. identified an association between luteinizing hormone/follicle-stimulating hormone deficiencies already with 22 Gy D~mean~ to the pituitary gland and hypothalamus on a lifetime cohort study of adult survivors of childhood cancers [@b0170]. In our cohort, the lowest pituitary D~mean~ was achieved with IMRT, with 21.4 Gy (range, 6.2--40.1 Gy), while PBS-T 21.8 Gy (range, 2.6--41.4 Gy) and VMAT 21.6 Gy (range, 1.7--40.0 Gy). Moreover, 30 Gy D~mean~ to the pituitary gland might cause growth hormone deficiency in ≤ 30% of patients, with 30--50 Gy affecting 50--100% [@b0175].

### 3.2.4. Other NOAR function {#s0070}

#### 3.2.4.1. Vision {#s0075}

The lacrimal glands, lenses and optic globes could be better spared with PBS-PT, comparing with photons (in D~max~, D~mean~, ID); yet better with IMRT, when compared to VMAT. The risk for keratoconjunctivitis sicca could be avoided, as in all modalities D~mean~ of each lacrimal gland was ≤25 Gy [@b0050]. The potential for cataract is low, as D~0.03cc~ of each lens was ≤10 Gy [@b0050], even \<6 Gy [@b0075], according to the recommended constraints.

The risk for neuropathic complication is extremely low, considering the low optic nerve dose presented in every RT modality. The lowest optic nerve D~max~ was achieved with IMRT. However, a statistically significant difference was reached in favor of IMRT (in D~mean~ and ID) only by comparing it with VMAT.

#### 3.2.4.2. Audition {#s0080}

To avoid tinnitus, the D~mean~ of the cochleae should be ≤32 Gy [@b0050], which was possible with all three techniques. The lowest cochlear D~mean~ was achieved with PBS-PT. However, a statistically significant difference was reached (in D~max~, D~mean~, ID) only by comparing IMRT with VMAT, in favor of the latter.

### 3.2.5. Other potential late toxicity {#s0085}

#### 3.2.5.1. Radionecrosis {#s0090}

The D~mean~ applied to the brainstem was 29.9 Gy (range, 24.9--34.3 Gy) for PBS-PT, 33.0 Gy (range, 28.7--36.3 Gy) for IMRT and 30.9 Gy (range, 28.7--36.6 Gy) for VMAT. According to Uy et al., exceeding the 30 Gy D~mean~ might increase the incidence of severe brainstem necrosis in 3% [@b0180]. Considering our pediatric cohort, a lower threshold should be taken into account. The lowest brainstem dose exposure was achieved with PBS-PT in all its dose-metrics. However, a statistically significant difference was reached only when compared to IMRT (−9.2% D~mean~ and ID).

With the applied dose to the temporal lobes (3.2.1., [Table 1](#t0005){ref-type="table"}), the risk for necrosis is very low.

#### 3.2.5.2. Myelopathy {#s0095}

Even though the spinal cord D~max~ of this cohort has not exceeded 30.2 Gy (IMRT) -- therefore, not expecting the risk of myelopathy --, the highest spinal cord sparing was achieved with VMAT. Compared with PBS-PT and IMRT, VMAT presented reduced D~mean~ (−47.2%, −39.3%) and ID (−45.1%, −43.1%).

#### 3.2.5.3. Alopecia {#s0100}

No permanent alopecia is expected, as D~0.03cc~ of the skin was ≤25 Gy [@b0050].

#### 3.2.5.4. Risk for secondary malignancy {#s0105}

Healthy brain tissue, as a potential risk area for secondary malignancy, could be spared mainly with protons: D~mean~ 12.0 Gy (range, 8--20.5 Gy) for PBS-PT, 18.5 Gy (range, 12.9--28.2 Gy) for IMRT and 17.9 Gy (range, 14.11--25.0 Gy) for VMAT. Despite no clinical proof of a sequelae difference regarding this dose level to the pediatric brain, it is known that even relatively low doses of radiation, once perceived as being "safe", may increase the probability of the development of secondary cancers [@b0185]. Therefore, the ALARA concept should be followed. Moreover, an ID reduction, as seen in the proton plans, is expected to result in a lower rate of secondary tumor induction after treatment [@b0190]. Compared to IMRT and VMAT, PBS-PT showed the following statistically significant differences:•normal brain (brain without PTV) -- D~max~ (−2.5%, −1.6%), D~mean~ (−35.2%, −32.7%) and ID (−35.2%, −33.0%, respectively);•supratentorial brain -- D~mean~ (−23.8%, −20.7%) and ID (−21.9%, −20.1%)•parotid glands -- D~max~ (left: −96.7%, −93.8%; right: −98.2%, −96.6%), D~mean~ (−100.0%, −100.0%) and ID (−100.0%, −100.0%).

The dose to the parotid glands is way below the recommended 20 Gy in every modality, meaning that the expected xerostomia will be below 20% [@b0195]. The PBS-PT dose is otherwise close to 0.0 Gy in every dose-metric, similar to the lenses and temporomandibular joints. In comparison, these healthy tissues would be susceptible to develop a secondary malignancy if this long-term survivor cohort would have been treated with photons.

3.3. Comparative evaluation of treatment plans {#s0110}
----------------------------------------------

RT planning with steep dose gradient is required to better spare the NOAR. Effective immobilization and accurate radiation delivery methods are therefore crucial to provide the higher degree of set-up reproducibility required. This varies with the immobilization type used and compliance of the patient. For PBS-PT plans, a 4 mm CTV-PTV margin for a bite-block immobilization system was applied at PSI. At Inselspital, a 3 mm margin for a frameless thermoplastic mask would have been used instead. On the one hand, the lowest margin could be advantageous in comparison to the 4 mm margin by reducing the NOAR volume irradiated, mainly from the thalamus ([Supplementary file Fig. A.1](#s0140){ref-type="sec"}, light blue VOI). On the other hand, within this 1 mm difference, the number of NOAR included in the PTV_Low is the same. Furthermore, the 3 mm expansion on one TPS showed similar volume to the 4 mm expansion on the other TPS, thus being cursory to perform an analysis comparing both.

IMRT with dose painting has been shown in dosimetric comparisons to provide the most conformal photon treatment for WV-RT [@b0200], [@b0205]. However, some studies raised concern about its possibility of creating a greater ID delivered mainly to the healthy brain [@b0210]. Another sparing approach with photons is VMAT, with reduced treatment delivery time compared to conventional static field IMRT [@b0215], which can be advantageous in a pediatric population. For future multiple-arc treatments, dynamic trajectory VMAT [@b0135], [@b0220] might be a good study objective to provide further improvements in OAR sparing in IGCT, especially when PT is not available.

PT is an acknowledgeable technique for normal tissue sparing in pediatric cranial RT, with its predicted consistently lower doses to critical normal tissues and ID to the body [@b0190] compared with photons [@b0150]. Regarding WV-RT, MacDonald published one demonstrative case of WV-RT/TB in localized IGCT (WV = 23.4 Gy, boost 45 Gy) where intensity-modulated proton therapy with fine pencil beams (σ = 3 mm) allowed additional sparing over IMRT and conformal PT (passive scattering or PBS) [@b0040]. Park presented a study with three WV-RT/TB cases (WV = 19.8 Gy, boost 30.6 Gy, normalized to get 100% of the D~p~ to 95% of the PTV), showing similar results [@b0225]. Extrapolating from prospective studies [@b0130], [@b0135], this approach might reduce the radiation-related late toxicity in survivors.

4. Conclusion {#s0115}
=============

Taking into account the ALARA concept, PBS-PT can be a reasonable alternative to photons for IGCT, as it seems to reduce dose exposure to the surrounding NOAR while keeping good target coverage and better conformality. Otherwise, IMRT seems dosimetrically superior to VMAT regarding the NOAR sparing in WV-RT/TB. Overall, technical attempts to potentially reduce the dose- and volume-related side effects of treatment in long-term survivors should be pursued, ideally on prospectively assessing outcome.
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[^1]: Abbreviations: VOI, volume of interest; PTV*,* planning target volume; D~max~, maximum dose of VOI; D~mean~, average dose of VOI; D~min~, minimum dose of VOI; ID, integral dose (D~mean~ × volume); V~90%~, percentage of PTV receiving a minimum of 90% of the prescribed dose; V~95%~, percentage of PTV receiving a minimum of 95% of the prescribed dose; V~100%~, percentage of PTV receiving a minimum of 100% of the prescribed dose; HI, homogeneity index ((D~5%~ − D~95%~)/prescribed dose × 100); IC, inhomogeneity coefficient ((D~max~ − D~min~)/D~mean~); CTV, clinical target volume; GTV, gross tumour volume; SVZ, subventricular zone; TMJ, temporomandibular joint.

[^2]: Indicates statistically significant differences (p \< 0.017) in the Friedman test with the Bonferroni posttest.
